'''Ocaperidone''' (also '''R 79598''') is a [[benzisoxazole]] [[antipsychotic]].<ref>{{cite journal|pmid=1372084|year=1992|last1=Leysen|first1=JE|last2=Janssen|first2=PM|last3=Gommeren|first3=W|last4=Wynants|first4=J|last5=Pauwels|first5=PJ|last6=Janssen|first6=PA|title=In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone|volume=41|issue=3|pages=494–508|journal=Molecular Pharmacology}}</ref> It was initially developed by [[Janssen Pharmaceutica|Janssen]], later licensed to French laboratory Neuro3D and then acquired in 2007 by German company [[Evotec]]. Its testing was abandoned after phase II trials, as of 22 February 2010.<ref>{{cite web|title=Ocaperidone — AdisInsight|url=http://adisinsight.springer.com/drugs/800001114|website=Adis Insight|publisher=Adis International Ltd, part of Springer Science+Business Media|accessdate=10 December 2015}}</ref>
